Sanofi (SNY) has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to Clayton, Dubilier & Rice (CD&R), a deal that underscores Opella's emergence as a standalone global leader in the sector. Sanofi maintains a substantial interest with a 48.2% shareholding, while Bpifrance acquires a 1.8% ownership, joining Opella's Board of Directors.
This transaction, which aligns with Sanofi's strategic objectives, brought in approximately EUR 10 billion in net cash proceeds. Sanofi's CEO expressed strong belief in Opella's potential as an independent entity, noting its robust team, deep consumer insights, and global reach as critical elements for its long-term success. Backed by CD&R's expertise in consumer healthcare and commitment to sustainability, Opella anticipates significant growth prospects ahead.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.